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 Human embryonic stem cells within blastocyst 
have made us what we are. The stem cells keep us 
young by endogenously repairing us upon need. 
They do so by smartly one step forward towards 
differentiation while another step backward to 
nurture the undifferentiated stem cells. This clinic is 
on-line and free for all target organs.  Thus, they are 
building blocks for every organ with differential rate 
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of repair of worn out tissues. It was the pioneering 
work of Wilmut et al.1 and Thomson et al.2 on the 
cloning and the identification of human embryonic 
stem cells that  initiated a new era for research in 
molecular stem cell biology leading to therapeutic 
potential. This review focuses on where we are on 
the status of heart repair and cardiac regeneration.3
What is the scope of cardiac stem cell research?: 
Fig.1 shows the components of this scope:
Perspective: It is aimed to provide cell replacement 
therapy to halt progressive heart failure and repair 
heart after myocardial infarction (MI).
Potential: Since stem cells can be cultured with a 
normal karyotype and regenerative potential, they 
could be the source for heart repair after MI.
Microenvironment: Since stem cells are controlled 
by a particular microenvironment, it is supported by 
feeding cells, basement membrane and biologically 
active molecules. Understanding the stem cell-
environment-interaction at the cellular, molecular 
and genetic levels forms the basis of biological 
repair of heart. The discovery of neural/cardiac 
Review Article
Is biological repair of 
Heart on the Horizon?
HR Ahmad1, Satwat Hashmi2
ABSTRACT
The stem cells keep us young by endogenously repairing us upon need. They do so by smartly one step 
forward towards differentiation while another step backward to nurture the undifferentiated stem cells. 
They are building blocks for every organ with a differential rate of repair of worn out tissues. Since stem 
cells can be cultured with a normal karyotype, they could be the ideal source for heart repair after 
myocardial infarction. As opposed to lower vertebrates and neonatal mice, cardiac regeneration in adult 
mammalian heart seems to be difficult to assess with a solid evidence of cytokinesis. It becomes more 
difficult to quantify the level of regeneration after myocardial infarction injury against a background of a 
large invasion of proliferating inflammatory cells. The question to be raised is how the renewal of a piece 
of myocardium follows the time line of picking up cell types in series: cardiomyocytes, endothelial cells, 
smooth muscle cells, fibro blast, pacemaker cells, conducting and Purkinje cells to bring the orchestration 
of rhythmically contracting and relaxing heart. This review focuses on where we are on the status of heart 
repair and cardiac regeneration.
KEYWORDS: Stem cells, Cardiomyocytes and Cardiac regeneration.
doi: https://doi.org/10.12669/pjms.334.12938
How to cite this:
Ahmad HR, Hashmi S. Is biological repair of Heart on the Horizon? Pak J Med Sci. 2017;33(4):1042-1046.   
doi: https://doi.org/10.12669/pjms.334.12938
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pak J Med Sci   2017   Vol. 33   No. 4      www.pjms.com.pk   1042
Biological repair of Heart 
stem cells has opened new opportunity of biological 
repair of brain and heart. However, they seem to be 
restricted regionally and temporally. It means that 
not all stem cells are equivalent. How good the bone 
marrow stem cells could home to heart to become 
the part of the working myocardium has been tried 
but with limited success. How long they would 
remain true to myocardium is not warranted.
Tissue Engineering: careful tissue engineering is 
required to produce an ideal mix of stem cells for 
the biological repair of diseased organs.  As stem 
cells have the tendency to be transformed into 
cancer cells, it could be considered as one of the 
sources of tumor-genesis in different target organs.4
Epigenetic inheritance: Of note is the fact that the 
genotypes of most cells are similar. Yet they show 
diversity in morphology [phenotype] and functions. 
It is because the selective expression and repression 
of genes that determine the specific properties 
of individual cells. What are signals that can 
reprogram differentiated cell back to totipotency 
need to be fully elucidated?
Ethical issues: Since resources of acquiring stem 
cells are many, ethical and social consideration 
of biological repair might pose with difficulty. 
Fig.1: Scope of stem cell research.
Fig.2: Schematic representation of key concepts in biological repair of heart.
(a) Shows time course of pre and post natal cardiac regeneration between lower vertebrates and human. Prenatally both 
species are regenerative friendly. Humans dissociate markedly from lower vertebrates postnatally.
(b) Is a cardiac mass response to MI between two species showing complete recovery in lower vertebrates.
(c) Shows hyperbolic relationship between regeneration and scar size in response to MI.
(d) Is a model showing how adult cardiomyocytes might regenerate in response to injury?
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Therefore, any use of stem cell therapy should 
be subjected to appropriate scientific and ethical 
review committee.
Is human heart post-mitotically locked?: We 
thought the mammalian heart to be post mitotically 
locked to live as long we live.5 However, this has 
been challenged with evidence of resident/homing 
stem cells for cardiac regeneration. Prenatally, 
this phenomenon is working well. However, this 
mechanism is switched off postnatal showing the 
stage of terminal differentiation. This transition 
might be associated with the transformation of 
hyperplasia to hypertrophy. DNA replication study 
with evidence of cytokinesis in cardiomyocytes 
is actively sought as a test of proliferation and 
regeneration.6,7 Since cytokinesis could not be 
evidenced in most studies, a quantitation of 
regeneration is difficult to assess.8,9 Loss of cardiac 
mass as a result of MI or progressive heart failure 
is a major cause of morbidity and mortality.10 
Since human heart is persistently scarred after MI, 
the endogenous cardiac regeneration seems to be 
inhibited by the scar formation11,12 (Fig.2c). 
Can heart be regenerated by cardiac resident and 
homing stem cells?: Findings in lower vertebrates 
and neonatal mice are encouraging but cardiac re-
generation in adult mammalian heart seems to be 
harder to assess with solid evidence (Fig.2a and b). 
It becomes more difficult to quantify the level of re-
generation after MI injury with a background of a 
large invasion of proliferating inflammatory cells. 
What are tools to assess cardiac regeneration capac-
ity? These include DNA synthesis labeling, trans-
genic mouse models and genetic lineage tracing 
based on molecular markers, multi-isotope imag-
ing mass spectrometry and immunohistochemistry 
and flow cytometry. Addition of nucleosides into 
the newly formed DNA shows a rate of less than 1% 
of cardiac regeneration per year. Non-cardiomyo-
cyte cells like fibroblasts, endothelial cells, smooth 
muscle cell and immune cells and lack of evidence 
of cytokinesis due to rigid sarcomeric membrane 
seem to be confounder how good the regenera-
tion rate could be estimated.13 Interestingly, vari-
ous methods using a transgenic mouse model with 
beta-galactosidase, 14C labeling of cardiomyocyte 
nuclei and multi-isotope imaging mass spectrom-
etry showed a renewal rate not more than 1-2% per 
year.6,8,9 However, to what extent these rates might 
increase after injury is not clear. Comparing mice 
with human’s rate of renewal in context of life span, 
this low level regenerative capacity may be of sig-
nificance in humans for on line acute repair of heart.
 The question to be raised is how the renewal of a 
piece of myocardium follows the time line of picking 
up cell types in series: cardiomyocytes, endothelial 
cells, smooth muscle cells, fibroblast, pacemaker 
cells, conducting and Purkinje cells to bring the 
orchestration of rhythmically contracting and 
relaxing heart. How do genes encode these various 
cellular programs need to be decoded by well-
designed genomic and proteomic methodologies. 
This experimentation might show if cardiomyocyte 
genome contained a dormant stem cell regeneration 
site that could be coaxed for the biological repair of 
heart.14,15
What are cellular sources of adult cardiac 
regeneration?: Since the DNA-labeling studies did 
not show the cellular source of regeneration in 
the adult or injured heart, cell transplantation and 
genetic lineage tracing based on molecular markers 
were tried.  Orlic et al.16 were the first to show a 68% 
regeneration of the infarcted myocardium in rodents 
in response to injection of Lin-c-Kit+ BMCs [Bone 
marrow cells]with a delay of 9 days. This showed 
that it took 9 days for processing the BMCs to cardiac 
cellular commitment, differentiation and functional 
maturation. The sad story is that the claims of this 
study could not be reproduced no matter how 
the cells were isolated and treated.17 BMCs could 
have provided paracrine cardioprotective factors 
to improve the cardiac function.18 What might be 
the underlying mechanisms are not known. Since 
cKit BMCs could not regenerate heart, cultured Lin-
cKit+ cardiac progenitor cells, however, showed 
initially a positive response to regenerate 70% of 
adult rodent hearts after MI injury.11 This study 
was also not confirmed in adult hearts.19 Uchida 
et al20 reported Sca1-derived cells as a source of 
myocardial renewal in the murine adult heart. 
Further studies showed that Sca-1-expressing cells 
in the heart could be endothelial progenitors.21 
How good could the Sca-1 lineage –traced CPCs 
contribute new cardiomyocytes to injured heart 
remains uncertain. However, the emerging 
consensus is that both c-Kit+ and Sca-1+ resident 
CPCs cannot differentiate and regenerate the heart 
with anew contracting myocardium. How to divert 
their endothelial programs into cardiomyocyte 
lineage remains to be seen. Another member 
walks into this family is cardiac – resident SP 
cells with a molecular marker of ABC transporter 
proteins being able  to trans differentiate into 
cardiomyocytes, endothelial cells and smooth 
muscle cells.22 These three marker proteins can be 
used to identify specific population of CPCs to be 
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coaxed into the cardiomyocyte lineage. Of note is 
the fact that during embryonic development the 
true cardiac progenitors Is1+ cells can give rise to all 
lineages found in the heart.23 Similarly epicardially 
derived cells differentiate into cardiomyocyte. 
How these prenatal programs could be activated 
in the adult heart as to be capable of generating 
new cardiomyocytes, are not elucidated.24 Genetic 
lineage tracing with 15N-thymidine labeling 
followed by imaging mass spectroscopy showed 
that the mammalian heart can be regenerated 
from preexisting cardiomyocytes however, being 
limited in potential.9 These cardiomyocytes might 
be involved in ongoing renewal, but their response 
to the extent of MI seems to be blunted. Since these 
cardiomyocytes are also refractory to cytokinesis, 
response to MI might depend on this. Factors 
blocking cytokinesis could be a genetic block, over 
expression of cyclin-D2, Rb proteins deficiency 
switching off cardiomyocyte cell cycle activity 
and the quantity of nucleation.13,25 These factors 
regulating molecular switches of cardiomyocyte 
proliferation with a normal cytokinesis should 
be experimentally understood as to how scar 
formation prevents regeneration of myocardium in 
response to MI.
What are challenges in biological repair of heart?: 
The real challenge is to gain insights of dynamics 
of fetal to adult cardiomyocyte gene expression 
encoding proteomics for a well-organized 
sarcomeres, t-tubules, and ion channels to ensure 
an endogenous repair of adult heart. The delivery 
method of cardiac repair is causing uncertainties 
in context of either an intravenous injection or 
direct coronary infusion of stem cells. The cellular 
engraftment rate of injected cells is rather low. 
Paracrine mediators like extra cellular matrix 
factors angiogenic growth factors and interleukins 
among others could stimulate regeneration from 
resident cardiac stem cells and/or cardiomyocytes. 
How rapidly newly formed cardiomyocytes mature 
in vivo/in vitro could provide restoration of cardiac 
function with less risk of arrhythmias? How to use 
and interpret the time line of cardiomyocyte progeny 
with essential cell lines of a beating myocardium? 
How to achieve this mission against the tide of risk 
factors of rejection, cancer conversion and maturity 
are challenges to understand and develop means of 
rectification for good news from the clinical trials.
What are implications for biological repair of 
heart?: Since the acute biological repair of adult 
heart seems to be driven mainly by the proliferation 
of cardiomyocytes and to a lesser extent by trans 
differentiation of cardiac progenitor cells [CPC], 
future line of action should be to therapeutically 
focus on these two pathways (Fig.2d). Alternative 
cell replacement therapies [CRT] should be 
sought to enhance the regenerative capacity of the 
myocardium with all functional cell lines enabling 
to join the orchestra of a beating heart. Trials with 
overall survival as an endpoint are awaited to 
ensure CRT to be adopted for the cost effective 
biological repair of heart.
What can we learn from cardiac progenitor cell-
based trials?: There is an interesting race between 
preclinical models and clinical trials. The award of 
the former depends on the later. Bolli et al.26 reported 
the first trial on autologous cKit+ CPCs from cardiac 
tissue being harvested during CABG. These cells 
were cultured and then injected through arterial 
bypass graft. Large size trial has been recommended 
with a cocktail of c-Kit+ CPCs and bone marrow 
derived stem cells to reduce infarct size and restore 
cardiac function after MI.27 Since the engraftment of 
transplanted cells remains low in most of the clinical 
trials so far, the potential benefits could be due to 
paracrine effect as opposed to transdifferentiation 
of injected cells into cardiomyocytes.28 Might it be 
possible to study the constituents of the paracrine 
mediators to repair heart instead of cell replacement 
therapy? On the front line are ES (embryonic stem) 
and iPS (induced pluripotent stem) cells to compete 
for biological repair of heart. Pre-differentiated-ES-
patch has been aimed to align cardiomyocytes with 
the ECM to ensue contractile force after adherence 
to the native porcine myocardium.29 Human ESC-
derived-cardiomyocytes have been shown to 
regenerate non-human primate hearts.30 The 
question arises is might it be possible to switch 
fibroblast in the MI-scar into the cardiomyocytes? 
Direct reprogramming of fibroblast into functional 
cardiomyocytes by factors such as micro-RNA 
has been shown by Ieda et al.31 and Jayawardena 
et al.32 How far these results from preclinical 
animal models could be transferred to human are 
challenges of heart repair depending upon good 
news from the clinical trials with the endpoint of 
appreciable survival.
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